Author:
Conejo Fabio,Ribeiro Henrique Barbosa,Spadaro André Gasparini,Godinho Roger Renault,Faig Sandro M.,Gabrilaitis Camila,Okada Mariana Y.,Spósito Alexandre,Espirito‐Santo Carlos Vinícius,Rodrigues Marcelo Jamus,Garcia J. Carlos Teixeira,Silva Pedro Gabriel Melo de Barros e,Furlan Valter,Ribeiro Expedito E.
Subject
Cardiology and Cardiovascular Medicine
Reference32 articles.
1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high‐risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994; 330(14):956‐61.
2. ; Society for Cardiovascular Angiography and Interventions;Chambers;Defining the length of stay following percutaneous coronary intervention: an expert consensus document from the Society for Cardiovascular Angiography and Interventions. Endorsed by the American College of Cardiology Foundation. Catheter Cardiovasc Interv.,2009
3. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low‐dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997; 336(24):1689‐96.
4. Twenty‐five‐year trends in in‐hospital and long‐term outcome after percutaneous coronary intervention;Singh;a single‐institution experience Circulation.,2007
5. The CAPTURE trial;Umans;Lancet.,1997
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献